2-O-β-D-Glucopyranosyl-L-ascorbic acid

Synonyms: 抗坏血酸葡糖苷; AA-2βG
2-O-β-D-Glucopyranosyl-L-ascorbic acid (AA-2βG) 是一种具有口服活性的维生素 C 衍生物,具有抗氧化、抗肿瘤、免疫调节等多种活性,可介导肿瘤细胞凋亡 (apoptosis)、诱导细胞周期阻滞,也可清除自由基、消除氧化应激,可用于癌症、炎症和免疫方面的相关研究。
产品编号: MS-R22347 纯度: 95.0% CAS No.: 562043-82-7 分子式: C12H18O11 分子量: 338.26
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

2-O-β-D-Glucopyranosyl-L-ascorbic acid (AA-2βG) 是一种具有口服活性的维生素 C 衍生物,具有抗氧化、抗肿瘤、免疫调节等多种活性,可介导肿瘤细胞凋亡 (apoptosis)、诱导细胞周期阻滞,也可清除自由基、消除氧化应激,可用于癌症、炎症和免疫方面的相关研究。

生物实验数据

生物活性 2-O-β-D-Glucopyranosyl-L-ascorbic acid (AA-2βG) is an orally active vitamin C derivative that exhibits multiple activities including antioxidant, antitumor, and immunomodulatory effects, mediates tumor cell apoptosis, induces cell cycle arrest, scavenges free radicals, and eliminates oxidative stress, and can be used in research related to cancer, inflammation, and immunity.
体外研究
(In Vitro)

2-O-β-D-Glucopyranosyl-L-ascorbic acid (1.0-5.0 mM; 24-72 h) 可呈时间和剂量依赖性地在 Hela、HS-746T 和 Colo-320 癌细胞中选择性诱导细胞毒性和抗增殖作用。
2-O-β-D-Glucopyranosyl-L-ascorbic acid (3.0 mM; 24-72 h) 可在 Hela 细胞中诱导呈剂量和时间依赖性的凋亡形态学改变,包括出现染色质浓缩、膜起泡和凋亡小体形成。
2-O-β-D-Glucopyranosyl-L-ascorbic acid (0.001-1.0 mM; 24-48 h) 可在 Hela 细胞中诱导呈时间和剂量依赖性的 G0/G1 期细胞周期阻滞。
2-O-β-D-Glucopyranosyl-L-ascorbic acid (5.0 mM; 24 h) 可下调 vinculin、mitofilin、热休克蛋白 60、α-微管蛋白、不均一核核糖核蛋白 H1、GAPDH 以及 c-Jun/AP-1 的蛋白表达水平,同时可上调 p53 的蛋白表达水平。
2-O-β-D-Glucopyranosyl-L-ascorbic acid (3.1-12.5 μM; 1 h) 可显著抑制过氧化氢诱导的小鼠巨噬细胞 RAW264.7 中的 ROS、超氧阴离子生成,恢复线粒体跨膜电位。
2-O-β-D-Glucopyranosyl-L-ascorbic acid (3.1-12.5 μM; 4 h) 可恢复经过氧化氢处理的小鼠巨噬细胞 RAW264.7 的细胞内 GSH 水平,降低 GSSG 水平,并提高 GSH/GSSG 比值。
2-O-β-D-Glucopyranosyl-L-ascorbic acid (3.1-12.5 μM; 4 h) 可恢复经过氧化氢处理的小鼠巨噬细胞 RAW264.7 中的超氧化物歧化酶和过氧化氢酶活性。
2-O-β-D-Glucopyranosyl-L-ascorbic acid (3.1-12.5 μM; 4 h) 可显著降低过氧化氢诱导的小鼠巨噬细胞 RAW264.7 的 LDH、TNF-α 释放。
2-O-β-D-Glucopyranosyl-L-ascorbic acid (12.5 μM; 4 h pretreatment) 可下调经过氧化氢处理的小鼠巨噬细胞 RAW264.7 中的 Keap-1 表达,并上调 Nrf2 和 HO-1 的表达。
2-O-β-D-Glucopyranosyl-L-ascorbic acid (12.5 μM; 4 h) 可促进经过氧化氢处理的小鼠巨噬细胞 RAW264.7 中 Nrf2 的核转位。

Cell Viability Assay

Cell Line: human cervix adenocarcinoma Hela cells, human gastric carcinoma HS-746T cells, human colorectal adenocarcinoma Colo-320 cells, human liver cancer Bel-7402 cells, human primary vascular endothelial VEC cells
Concentration: 1.0 mM, 2.0 mM, 3.0 mM, 4.0 mM, 5.0 mM
Incubation Time: 24 h, 48 h, 72 h
Result: Induced cytotoxicity and antiproliferative effects in a cell type-, time-, and dose-dependent manner.
Caused 90% cell death in Hela cells treated with 5.0 mM for 72 h.
Reduced cell viability significantly in HS-746T and Colo-320 cells, with greater effects at higher concentrations and longer incubation times.
Showed moderate inhibition or slight promotion of cell viability in Bel-7402 cells and VEC cells.

Cell Cycle Analysis

Cell Line: human cervix adenocarcinoma Hela cells
Concentration: 0.001 mM, 0.01 mM, 0.1 mM, 1.0 mM
Incubation Time: 24 h, 36 h, 48 h
Result: Increased G0/G1 phase cell fraction and decreased S phase cell fraction in a time- and dose-dependent manner, indicating G0/G1 phase cell cycle arrest.
Resulted in 58.58% G0/G1 and 31.22% S phase cells with 0.001 mM treatment for 48 h.
Caused 60.95% G0/G1 and 26.72% S phase cells with 0.01 mM treatment for 48 h.
Induced 72.02% G0/G1 and 22.85% S phase cells with 0.1 mM treatment for 48 h.
Led to 85.16% G0/G1 and 11.16% S phase cells with 1.0 mM treatment for 48 h.
Raised G0/G1 fraction to 74.30% at 24 h, 80.69% at 36 h, and 85.16% at 48 h, while decreasing S phase fraction to 21.0% at 24 h, 14.27% at 36 h, and 11.16% at 48 h with 1.0 mM treatment.

Western Blot Analysis

Cell Line: hydrogen peroxide (H2O2)-treated murine macrophage RAW264.7 cells
Concentration: 12.5 μM
Incubation Time: 4 h (pretreatment prior to 6 h H2O2 stimulation)
Result: Downregulated H2O2-induced Keap-1 expression, and significantly reversed H2O2-suppressed Nrf2 and HO-1 expression levels, with statistically significant effects (p < 0.01) observed for all three proteins relative to H2O2-only treatment.

Immunofluorescence

Cell Line: hydrogen peroxide (H2O2)-treated murine macrophage RAW264.7 cells
Concentration: 12.5 μM
Incubation Time: 4 h (pretreatment prior to 6 h H2O2 stimulation)
Result: Induced nuclear translocation of Nrf2 following H2O2 stimulation, with increased Nrf2 fluorescence observed in the nuclear compartment relative to H2O2-only treatment.
体内研究
(In Vivo)

2-O-β-D-Glucopyranosyl-L-ascorbic acid (100 mg/kg;灌胃;32 天) 在 Cyclophosphamide (MS-C45849) 诱导的免疫抑制 BALB/c 小鼠中发挥显著的免疫调节活性。

Animal Model: BALB/c treated Cyclophosphamide (MS-C45849) (5-week-old, 16 ± 1.0 g)
Dosage: 100 mg/kg BW/day
Administration: intragastric gavage; daily; 32 consecutive days
Result: Significantly reversed cyclophosphamide-induced body weight loss, colon length reduction, and decreases in thymus and spleen indexes.
Significantly reversed cyclophosphamide-induced increases in neutrophil and monocyte percentages and decrease in lymphocyte percentage, with no significant effect on eosinophil percentage.
Significantly reversed cyclophosphamide-induced down-regulation of TNF-α, up-regulation of TGF-β1, and decrease in IgA levels; no significant effect on IL-10 levels.
Significantly reversed cyclophosphamide-induced decreases in hepatic GSH, CAT, and SOD levels and increase in ALT level; no significant effect on hepatic MDA level).
Prevented cyclophosphamide-induced histopathological damage to jejunum, colon, and liver tissue, maintaining intact villi structure and preventing liver focal solidification necrosis and vacuolar degeneration.
Significantly reversed cyclophosphamide-induced reductions in cecal i-butyric and i-valeric acid concentrations.
Reversed cyclophosphamide-induced increases in Epsilonbacteraeota and Proteobacteria relative abundances and decreases in Patescibacteria and Tenericutes relative abundances in colonic microbiota; reversed cyclophosphamide-induced changes in relative abundances of 13 bacterial families; significantly altered 61 colonic microbial functional modules compared to the cyclophosphamide-only group, including enriching amino acid metabolism/synthesis pathways and depleting disease-related pathways.
Significantly increased Bacteroidetes relative abundance, decreased Firmicutes relative abundance, and reversed cyclophosphamide-induced increase in Proteobacteria relative abundance in small-intestinal microbiota; significantly increased Muribaculaceae relative abundance and decreased Desulfovibrionaceae and Paenibacillaceae relative abundances compared to the cyclophosphamide-only group; significantly altered 119 small-intestinal microbial functional modules compared to the cyclophosphamide-only group, including enriching DNA replication/transcription/translation pathways, amino acid biosynthesis, and energy metabolism pathways, and depleting disease-related pathways.
性状 固体
颜色 White to light yellow

化学信息

分子量 338.26
分子式 C12H18O11
CAS No. 562043-82-7
别名 抗坏血酸葡糖苷; AA-2βG

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : ≥ 250 mg/mL (739.08 mM)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM2.9563 mL14.7815 mL29.5631 mL73.9076 mL
5 mM0.5913 mL2.9563 mL5.9126 mL14.7815 mL
10 mM0.2956 mL1.4782 mL2.9563 mL7.3908 mL
15 mM0.1971 mL0.9854 mL1.9709 mL4.9272 mL
20 mM0.1478 mL0.7391 mL1.4782 mL3.6954 mL
25 mM0.1183 mL0.5913 mL1.1825 mL2.9563 mL
30 mM0.0985 mL0.4927 mL0.9854 mL2.4636 mL
40 mM0.0739 mL0.3695 mL0.7391 mL1.8477 mL
50 mM0.0591 mL0.2956 mL0.5913 mL1.4782 mL
60 mM0.0493 mL0.2464 mL0.4927 mL1.2318 mL
80 mM0.0370 mL0.1848 mL0.3695 mL0.9238 mL
100 mM0.0296 mL0.1478 mL0.2956 mL0.7391 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础